Alia Therapeutics
MILAN, ITALY / ACCESSWIRE / May 9, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Adel Nada as an independent member of the Board of Directors.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Adel Nada is Co-founder and Chief Executive Officer of GentiBio, a biotherapeutics company that is developing engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics, where he worked on advancing engineered regulatory T cell therapeutics.
Over the past 15 years, he has successfully led translational and immunology programs for experimental and approved therapies, spanning small and large molecules, as well as engineered immune cell products.
Paola Pozzi, Partner at Sofinnova Partners and a member of Alia's Board of Directors, said: "Adel's experience and knowledge of the field will help guide Alia towards the next stage in its development. We feel very fortunate to have such an esteemed leader join our Board of Directors."
Adel Nada, Independent Board Director of Alia, said: "I'm delighted to have been invited to join the board of such a compelling biotech with a very differentiated genome editing platform. I look forward to advancing Alia's platforms and pipeline to enable novel, tailored gene editing strategies that have the potential to overcome current limitations of genome editing and bring more therapies to patients with underserved and currently untreatable diseases and conditions."
Letizia Goretti, Chief Executive Officer of Alia, said: "Adel's experience in biotech is both broad and deep. We are really excited to partner with him as Alia's growth accelerates."
Adel received his medical degree from Alexandria University in Egypt and his master's degree in clinical research from the Pharmacology Dept. at Rush University in Chicago, where he also held an academic position and practiced for 10 years in affiliated hospitals.
About Alia Therapeutics
Alia Therapeutics is an Italian biotech start-up whose mission is to develop innovative treatments for incurable genetic diseases using gene editing technology. The company was founded in October 2018 by Anna Cereseto and a group of researchers from CIBIO, the biotech department of the University of Trento, who discovered the core CRISPR technologies exploited by the start-up. Read more at aliatherapeutics.com
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
For more information about Sofinnova Telethon, visit https://sofinnovapartners.com/strategy/telethon
Contact
Letizia Goretti
CEO, Alia Therapeutics
info@aliatx.com
SOURCE: Alia Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/753506/Alia-Therapeutics-appoints-Adel-Nada-as-Independent-Board-Director
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Nestlé and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona9.5.2025 04:20:00 CEST | Press release
BARCELONA, ES / ACCESS Newswire / May 9, 2025 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Symposium/Xpo™ 2025 to attend Nestlé's solution provider session on May 19. The presentation will highlight how the company is transforming its supply chain across brands and regions using OMP's Unison PlanningTM. In this session, Shannon Novack, Supply Chain Excellence Expert at Nestlé, will share how the global food and beverage leader is reimagining its supply chain planning to meet increasing customer expectations in a fast-changing business environment. By leveraging advanced planning technology like Unison Planning, managing organizational change, and scalingfuture-fit capabilities, Nestlé is delivering real results. Attendees will gain valuable insights into how the company is driving adoption, overcoming transformation challenges, and aligning technology speed with organizational agility. The Gartner Supply Chain Symposium/Xpo
Innodata Reports First Quarter 2025 Results with Revenue up 120% Year-Over-Year and Reaffirms Growth Guidance of 40% or more for 20258.5.2025 16:45:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2025. Revenue of $58.3 million, representing 120% revenue growth year-over-year. Adjusted EBITDA of $12.7 million, an increase of $8.9 million from $3.8 million in the same period last year.* Net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, compared to a net income of $1.0 million, or $0.03 per basic and diluted share, in the same period last year. Cash, cash equivalents and short-term investments were $56.6 million as of March 31, 2025 and $46.9 million as of December 31, 2024. * Adjusted EBITDA is defined below. Jack Abuhoff, CEO, said, "We had a strong start to the year. We're being onboarded by potential major new customers, expanding existing relationships, and building a pipeline that's deeper and more advanced than at any point in our history. We are bringing ideas and innovation to our customers that are being w
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft8.5.2025 12:00:00 CEST | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 8, 2025 / The UK's Military Aviation Authority has issued a Military Type Certificate to the Royal Air Force's Protector RG Mk1 uncrewed aircraft, also designated the MQ-9B, certifying that it has passed a rigorous airworthiness assessment and verifying it's safe to operate without geographic restrictions, including over populous areas. This April 29 decision was a first-of-its-kind milestone for a large, unmanned aircraft system. It's a huge accomplishment for the UK and a technological watershed in the history of unmanned aircraft systems. GA-ASI is the first manufacturer of large, unmanned aircraft to receive an MTC based on rigorous compliance with STANAG 4671, the NATO standard for unmanned aircraft system airworthiness. Obtaining the MTC has been a goal of GA-ASI since the inception of the MQ-9B in January 2014. The company took its proven UAS platform, the MQ-9A, and added performance enhancing features while ensuring that the design
The Battery Show Europe 2025 Critical Agenda Highlights Moves to Global Collaboration, Regulation and Supply Chain Resilience8.5.2025 04:00:00 CEST | Press release
Featuring speakers from BMW, CATL, Mercedes Benz, Cellforce and more. STUTTGART, GERMANY / ACCESS Newswire / May 8, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany, the region's only dedicated event for battery manufacturing, electric and hybrid vehicle tech industries, has announced its 2025 keynote lineup. The sessions will cover key themes including upcoming supply chain, navigating regulatory and policy changes and staying ahead of the curve on market trends with analysis. "Better Together: Building Resilient Battery Supply Chains Through International Collaboration," opens the program moderated by James Frith, Principal at Volta Energy Technologies, featuring insights from Isobel Sheldon, Global CEO at Western CAM Inc, Ulderico Ulissi, Head of Overseas Tech & Start-up Cooperation at CATL, Jerry Fang, Director of Business Development at Shanghai Putailai New Energy Technology Co., Ltd. and Benoit Lem
Aster Guardians Global Nursing Award Unveils Top 10 Finalists for 2025 from 100,000+ Registrations7.5.2025 10:30:00 CEST | Press release
Over 100,000 registrations received from nurses across 199* countries - a 28% increase from the third edition, which received 78,000+ registrations. One of the shortlisted Top 10 finalists will be honoured with the grand title award and a prize of USD 250,000. These finalists were selected following a rigorous evaluation process, led by esteemed expert jury and grand jury panels. The entire process is independently moderated by the appointed "Process Advisors" Ernst & Young LLP. DUBAI, AE / ACCESS Newswire / May 7, 2025 / Aster DM Healthcare has today announced the Top 10 finalists for the fourth edition of Aster Guardians Global Nursing Award - a prestigious global recognition with USD 250,000 prize money, that honours the exceptional contributions of nurses worldwide. These 10 finalists were selected from a record-breaking pool of 100,000+ registrations across 199* countries, through a stringent evaluation process led by expert jury and Grand jury panels members. The entire process i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom